Ross L. Levine
Auto-generated profile, based on publicly available information

Ross L. Levine

Memorial Sloan Kettering Cancer Center

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2010 in Cancer Cell
Verified
Journal Article
Closed access
MFMaria E. Figueroa
Maria E. Figueroa
OAOmar Abdel-Wahab
Omar Abdel-Wahab
CLChao Lu
Chao Lu
PWPatrick S. Ward
Patrick S. Ward
JPJay Patel
Jay Patel
AMAri Melnick
Ari Melnick

22 March 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JPJay P. Patel
Jay P. Patel
MGMithat Gönen
Mithat Gönen
MFMaria E. Figueroa
Maria E. Figueroa
HFHugo Fernandez
Hugo Fernandez
ZSZhuoxin Sun
Zhuoxin Sun
RLRoss L. Levine
Ross L. Levine
Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in a phase 3 trial of treatment for AML. We performed a mutational analysis of 18 genes in 398 patients younger than 60 years of age who had AML and who were randomly assigned to receive induction therapy with high-dose or standard-dose daunorubicin. We validated our prognostic findings in an independent set of 104 patients. We identified at least one somatic alteration in 97.3% of the patients. We found that internal tandem duplication in FLT3 (FLT3-ITD), partial tandem duplication in MLL (MLL-PTD), and mutations in ASXL1 and PHF6 were associated with reduced overall survival (P=0.001 for FLT3-ITD, P=0.009 for MLL-PTD, P=0.05 for ASXL1, and P=0.006 for PHF6); CEBPA and IDH2 mutations were associated with improved overall survival (P=0.05 for CEBPA and P=0.01 for IDH2). The favorable effect of NPM1 mutations was restricted to patients with co-occurring NPM1 and IDH1 or IDH2 mutations. We identified genetic predictors of outcome that improved risk stratification among patients with AML, independently of age, white-cell count, induction dose, and post-remission therapy, and validated the significance of these predictors in an independent cohort. High-dose daunorubicin, as compared with standard-dose daunorubicin, improved the rate of survival among patients with DNMT3A or NPM1 mutations or MLL translocations (P=0.001) but not among patients with wild-type DNMT3A, NPM1, and MLL (P=0.67). We found that DNMT3A and NPM1 mutations and MLL translocations predicted an improved outcome with high-dose induction chemotherapy in patients with AML. These findings suggest that mutational profiling could potentially be used for risk stratification and to inform prognostic and therapeutic decisions regarding patients with AML. (Funded by the National Cancer Institute and others.)

1 July 2011 in Cancer Cell
Verified
Journal Article
Closed access
KMKelly Moran-Crusio
Kelly Moran-Crusio
LRLinsey Reavie
Linsey Reavie
ASAlan Shih
Alan Shih
OAOmar Abdel-Wahab
Omar Abdel-Wahab
DNDelphine Ndiaye-Lobry
Delphine Ndiaye-Lobry
RLRoss L. Levine
Ross L. Levine

1 September 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
CCCatherine C. Coombs
Catherine C. Coombs
AZAhmet Zehir
Ahmet Zehir
SDSean M. Devlin
Sean M. Devlin
AKAshwin Kishtagari
Ashwin Kishtagari
ASAijazuddin Syed
Aijazuddin Syed
MBMichael F. Berger
Michael F. Berger

23 September 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LBLambert Busque
Lambert Busque
JPJay P Patel
Jay P Patel
MFMaria E Figueroa
Maria E Figueroa
AVAparna Vasanthakumar
Aparna Vasanthakumar
SPSylvie Provost
Sylvie Provost
RLRoss L Levine
Ross L Levine
Ross Levine, Lambert Busque and colleagues report the identification of recurrent somatic mutations in TET2 in elderly female individuals with clonal hematopoiesis. The mutations were identified in individuals without clinically apparent hematological malignancies. Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated by X-inactivation analysis, identified somatic TET2 mutations. Recurrence testing identified TET2 mutations in 10 out of 182 individuals with X-inactivation skewing. TET2 mutations were specific to individuals with clonal hematopoiesis without hematological malignancies and were associated with alterations in DNA methylation.

26 October 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KBKelly L. Bolton
Kelly L. Bolton
RPRyan N. Ptashkin
Ryan N. Ptashkin
TGTeng Gao
Teng Gao
LBLior Braunstein
Lior Braunstein
SDSean M. Devlin
Sean M. Devlin
EPElli Papaemmanuil
Elli Papaemmanuil